manilatimes23h
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...
Business Insider1d
BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...
FiercePharma21h
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
TCTMD1d
Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality
The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.
pharmaphorum1d
Bayer pays $310m for Euro rights to ATTR therapy acoramidis
putting some big pharma muscle behind the therapy for transthyretin amyloid cardiomyopathy (ATTR CM). The deal includes upfront and near-term payments of $310 million for exclusive marketing ...
pharmaphorum4d
Alnylam hails vutrisiran data, but investors seem sceptical
Alnylam’s chief medical officer, Pushkal Garg, said the data “suggest[s] that vutrisiran has the potential to become a new standard of care treatment for ATTR-CM, a progressive and ultimately ...
marketinference1d
FDA Approves BridgeBio Pharma's ATTR-CM Treatment
This approval is based on positive results from the attribute-cm phase 3 study, which enrolled 632 participants with symptomatic ATTR-CM. The results from the study demonstrated significant ...
manilatimes23h
AGF Management Limited Declares Fourth Quarter 2024 Dividend
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- On December 13, 2024, the Board of Directors of AGF Management Limited declared a ...